Exhibit 10.6
RELEASE AGREEMENT
This Release Agreement (this "Agreement") is entered into as of June 23,
2006, by and among AKSYS, LTD., a Delaware corporation (the "Company"), DURUS
LIFE SCIENCES MASTER FUND LTD., a Cayman Islands company ("Durus"), ARTAL LONG
BIOTECH PORTFOLIO LLC, a Delaware limited liability company ("Artal") and
certain members of the Company's Board of Directors as set forth on the
signature page hereof (each, a "Director" and, collectively, the "Directors").
Durus and Artal are collectively referred to herein as the "Investors," and each
is individually referred to herein as an "Investor."
WHEREAS, the Company and Durus have entered into a Securities Purchase
Agreement by and among the Company and Durus, dated as of March 31, 2006 (the
"Purchase Agreement"), pursuant to which, among other things, the Company has
agreed, upon the terms and subject to the conditions set forth in the Purchase
Agreement, to issue and sell to Durus at the "Initial Closing," as defined in
the Purchase Agreement, (i) 5,000 shares of the Company's Series B Convertible
Preferred Stock, and (ii) warrants to purchase 5,000,000 shares of Common Stock
of the Company at an initial exercise price of $1.10 per share;
WHEREAS, contemporaneously with the execution and delivery of the Purchase
Agreement, (i) Durus made a bridge loan to the Company in an aggregate principal
amount of $5,000,000, pursuant to which the Company issued a note to Durus (the
"Bridge Loan"), (ii) the Company and Computershare Trust Company, Inc., as
successor Rights Agent under the Company's Rights Agreement, dated as of October
28, 1996, as amended (the "Rights Agreement"), executed and delivered an
amendment to the Rights Agreement in the form attached as Exhibit G to the
Purchase Agreement, and (iii) the Company and the Investors executed and
delivered an Amendment to the Settlement Agreement (as defined below)
substantially in the form attached as Exhibit H to the Purchase Agreement (the
"Settlement Agreement Amendment");
WHEREAS, contemporaneously with the Initial Closing, (i) Durus and the
Company will execute and deliver a loan agreement, substantially in the form
attached as Exhibit D to the Purchase Agreement (the "Loan Agreement"), pursuant
to which the Company will issue certain notes to Durus, (ii) the Investors and
the Company will execute and deliver an investor rights agreement, substantially
in the form attached as Exhibit E to the Purchase Agreement (the "Investor
Rights Agreement" and, together with the Purchase Agreement, the Bridge Loan,
the Settlement Agreement Amendment, the Loan Agreement and the other agreements
and documents entered into among the Company, Durus and/or Artal in connection
with the transactions contemplated in such agreements, the "Financing
Documents"), and (iii) certain of the Directors are resigning from their
positions as members of the Board of Directors of the Company and members of
certain committees thereof;
WHEREAS, the Company and the Investors have previously entered into certain
agreements with respect to the Investors' acquisition, ownership, trading and
disposition of shares of Common Stock of the Company and certain other matters,
including (i) a Settlement Agreement and Mutual Release dated as of February 23,
2004 (the "Settlement Agreement") by and among the Company, the Investors, Durus
Capital Management, LLC ("Durus LLC"), Durus
Capital Management (N.A.), LLC ("Durus NA") and ▇▇▇▇▇ ▇▇▇▇▇▇ ("Sacane" and,
together with Durus LLC and Durus NA, the "Sacane Parties"), (ii) a First
Amendment to Rights Agreement by and between the Company and EquiServe Trust
Company, N.A., as successor Rights Agent, dated as of February 23, 2004 (the
"First Rights Agreement Amendment"), (iii) the Registration Rights Agreement by
and among the Company and the Investors dated as of February 23, 2004 (the
"Registration Rights Agreement"), (iv) the Note Purchase Agreement by and among
the Company and the Investors dated as of February 23, 2004 (the "Note Purchase
Agreement"), pursuant to which the Company issued to the Investors unsecured
subordinated promissory notes (the "Notes" and, together with the Settlement
Agreement, the Rights Agreement, the First Rights Agreement Amendment, the
Registration Rights Agreement and the Note Purchase Agreement, the "Prior
Agreements");
WHEREAS, in connection with the execution and delivery of the Financing
Documents, it is the desire and intent of the Investors to fully and completely
waive, release and relinquish certain claims and rights that they may have
against the Company as set forth below, and it is the desire and intent of the
Company to fully and completely waive, release and relinquish certain claims and
rights that it may have against the Investors as set forth below; and
WHEREAS, it is the intent of each of the Directors to fully and completely
waive, release and relinquish certain claims and rights that such Director may
have against the Investors as set forth below.
NOW, THEREFORE, in consideration of the premises and the mutual covenants
contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto hereby agree as
follows:
1. RELEASE OF THE COMPANY.
As of the date hereof, each Investor for (i) itself and its affiliates
(other than the Company to the extent the Company might otherwise be deemed to
be an affiliate of such Investor) and subsidiaries, predecessor and successor
corporations or entities, (ii) any and all of their respective past, present and
future officers, directors, employees, agents, representatives and attorneys,
and (iii) any and all other persons, firms, corporations and entities that could
or might act on its behalf, does hereby fully, finally and forever release,
remise, discharge and acquit the Company, its affiliates and subsidiaries,
predecessor and successor corporations or entities, any and all of their
respective past, present and future managers, partners, officers, directors
(including the Directors), employees, agents, representatives and attorneys,
permitted assigns and transferees, and any and all other persons, firms,
corporations and entities that could or might act on its behalf (collectively,
the "Company Released Parties"), from and against any and all claims, actions,
causes of action, debts, damages, demands, offsets, payments, costs, attorneys'
fees, obligations of every kind and nature, rights, liabilities, charges,
expenses, contracts, promises and agreements (collectively, "Claims") arising
out of conduct to date, whether direct or indirect, regardless of the legal
theory upon which they are based, whether known or unknown, now existing or
arising at any time in the future, and whether liquidated or unliquidated,
including, but not limited to, (i) all Claims arising out of conduct to date
relating to or arising from the acquisition, ownership, trading or disposition
of shares of the Company's Common Stock, (ii) all Claims arising out of conduct
to date relating to breach of good faith or fair dealing or breach of
2
the duty of care or any other similar fiduciary duty, and (iii) all Claims
arising out of conduct to date relating to or arising under any agreement,
contract or other arrangement, whether verbal or written, entered into prior to
the Initial Closing, including the Prior Agreements. Notwithstanding the
foregoing, it is further expressly agreed that the terms of this Section 1 shall
not (i) release or otherwise discharge the obligations of the Company Released
Parties under or pursuant to the Financing Documents, (ii) apply to any Claims
such Investor (or any of its affiliates or other parties on whose behalf such
Investor is releasing Claims) may have against the Sacane Parties or (iii) apply
to any Claims such Investor (or any of its affiliates or other parties on whose
behalf such Investor is releasing Claims) may have relating to (A) any breach by
a Company Released Party of his or her duty of loyalty to the Company or its
stockholders, (B) any acts or omissions by a Company Released Party which
involve intentional misconduct or a knowing violation of law by him or her or
(C) any transaction from which an improper personal benefit was derived by a
Company Released Party.
2. RELEASE OF THE INVESTORS.
As of the date hereof, (1) each Director and (1) the Company for (i) itself
and its affiliates (other than the Investors to the extent the Investors might
otherwise be deemed to be affiliates of the Company) and subsidiaries,
predecessor and successor corporations or entities, (ii) any and all of their
respective past, present and future officers, directors, employees, agents,
equityholders, representatives, attorneys and joint venturers, and (iii) any and
all other persons, firms, corporations and entities that could or might act on
its behalf, does hereby fully, finally and forever release, remise, discharge
and acquit each of the Investors, their affiliates and subsidiaries, predecessor
and successor corporations or entities, any and all of their respective past,
present and future managers, investors, members, partners, officers, directors,
employees, agents, representatives and attorneys, permitted assigns and
transferees, and any and all other persons, firms, corporations and entities
that could or might act on its behalf, including, without limitation, Durus Life
Sciences Fund, LLC and Durus Life Sciences International Fund Ltd.
(collectively, the "Investor Released Parties"), from and against any and all
Claims arising out of conduct to date, whether direct or indirect, regardless of
the legal theory upon which they are based, whether known or unknown, now
existing or arising at any time in the future, and whether liquidated or
unliquidated, including, but not limited to (i) all Claims arising out of
conduct to date relating to or arising from the acquisition, ownership, trading
or disposition of shares of the Company's Common Stock, (ii) all Claims arising
out of conduct to date relating to breach of good faith or fair dealing or
breach of the duty of care or any other fiduciary duty, and (iii) all Claims
arising out of conduct to date relating to or arising under any agreement,
contract or other arrangement, whether verbal or written, entered into prior to
the Initial Closing, including the Prior Agreements. Notwithstanding the
foregoing, it is further expressly agreed that the terms of this Section 2 shall
not (i) release or otherwise discharge the obligations of the Investor Released
Parties under or pursuant to the Financing Documents, (ii) apply to any Claims
that the Company (or any of its affiliates or other parties on whose behalf the
Company is releasing Claims) or any Director may have may have against the
Sacane Parties, or (iii) apply to any Claims the Company (or any of its
affiliates or other parties on whose behalf the Company is releasing Claims) or
any Director may have relating to (A) a breach of any duty of loyalty that the
Investor Released Parties may have to the Company or its stockholders, (B) any
acts or omissions of the Investor Released Parties which involve intentional
misconduct or a knowing violation of law or (C) any
3
transaction from which an Investor Released Party derived an improper personal
benefit in breach of a duty to the Company or its stockholders.
3. FURTHER ASSURANCES.
(A) Subject to obligations under Applicable Law (as defined in Section 3(c)
below), each party hereto agrees that neither such party nor, as applicable, (i)
any of such party's affiliates and subsidiaries, predecessor and successor
corporations or entities, (ii) any of such party's past, present and future
officers, directors, employees, agents, representatives and attorneys, or (iii)
any other private person or private entity, including any individual, limited
liability company, partnership, joint venture, corporation, trust,
unincorporated organization but excluding any Governmental Body (as defined
below) (each, a "Private Person"), that such party controls or that could or
might act on its behalf, will assist, directly or indirectly, any other Private
Person in investigating, preparing or asserting any private action, suit,
litigation, arbitration, proceeding, contest, hearing, inquiry, inquest, audit
or examination (collectively, "Private Proceedings") against any person, party
or entity released hereunder arising out of conduct to date or any transaction
contemplated by this Agreement; provided, that nothing contained in this Section
3 shall preclude any such Private Person from producing documents or other
information or providing truthful testimony in response to a subpoena, court
order, regulatory request or other legal process believed in good faith to be
valid.
(B) Each party hereto agrees not to pursue any claim, right or defense
against any other party hereto under this Agreement that is inconsistent with
the obligations of such party under this Agreement. Each party hereto agrees
that it will not make any representation or argument or take any position
inconsistent with the agreements made by it in this Agreement, in any Private
Proceeding, including in any negotiation with any Private Person threatening to
make any claims or commence any Private Proceeding, and no party hereto shall
initiate or encourage in any way any such Private Proceeding.
(C) "Applicable Law" as used herein means all controlling applicable
federal, state and local statutes, regulations, ordinances and administrative
rules and orders (that have the effect of law) as well as all applicable final,
non-appealable judicial opinions.
(D) "Governmental Body" as used herein means any governmental authority,
agency or entity of any kind whatsoever, including without limitation any
quasi-governmental agency, self-regulatory organization, arbitrator or arbitral
panel.
4. SUFFICIENCY OF CONSIDERATION.
Each Investor, the Company and each Director acknowledges and agrees that
sufficient consideration has passed among them by virtue of this Agreement to
render this Agreement, including the releases herein, valid and enforceable.
5. AMENDMENTS; WAIVERS.
4
This Agreement may not be modified, amended, or terminated except by an
instrument in writing, signed by each of the parties; provided, further, that no
such modification, amendment or termination shall adversely affect the rights of
any beneficiary of this release without that beneficiary's written consent. No
failure to exercise and no delay in exercising any right, remedy, or power under
this Agreement shall operate as a waiver thereof, nor shall any single or
partial exercise of any right, remedy, or power under this Agreement preclude
any other or further exercise thereof, or the exercise of any other right,
remedy, or power provided herein or by law or in equity.
6. ENTIRE AGREEMENT.
This Agreement and the Transaction Documents (as defined in the Purchase
Agreement) constitute the complete, final and exclusive embodiment of the entire
agreement among the parties hereto with regard to the subject matter hereof and
thereof. This Agreement is entered into without reliance on any promise or
representation, written or oral, other than those expressly contained or
referenced herein.
7. HEIRS, SUCCESSORS AND ASSIGNS.
This Agreement shall bind the heirs, personal representatives, successors,
assigns, executors and administrators of each party hereto, and inure to the
benefit of each such party, its heirs, personal representatives, successors,
assigns, executors and administrators.
8. MISCELLANEOUS.
(A) The execution of this Agreement shall neither constitute nor be
construed as an admission of any liability.
(B) This Agreement shall be governed by and construed in accordance with
the law of the State of Delaware, without giving effect to the conflicts or
choice of law provisions thereof.
(C) If any provision of this Agreement is determined to be invalid, void or
unenforceable, in whole or in part, this determination will not affect any other
provision of this Agreement, and the provision in question shall be modified so
as to be rendered valid and enforceable and to give the applicable parties
hereto the intended benefits of the provision.
(E) The parties hereto acknowledge and agree that the provisions of this
Agreement are intended to be for the benefit of, and may be enforced by, each of
the parties and the third parties who are intended beneficiaries of the release
of claims against them contained in Sections 1 and 2 hereof.
(F) This Agreement may be executed in one or more counterparts, each of
which will be deemed to be an original and all of which, when taken together,
will be deemed to constitute one and the same document.
5
IN WITNESS WHEREOF, the Investors, the Company and the Directors have
caused their respective signature page to this Release Agreement to be duly
executed as of the date first written above.
AKSYS, LTD.
By: /s/
------------------------------------
Name:
Title:
DURUS LIFE SCIENCES MASTER FUND LTD.
By: /s/
------------------------------------
Name:
Title:
ARTAL LONG BIOTECH PORTFOLIO LLC
By: Artal Alternative Treasury
Management
Its: Managing Member
By: /s/
------------------------------------
Name:
Title:
6
/s/
----------------------------------------
▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
/s/
----------------------------------------
▇▇▇▇ ▇. ▇▇▇▇▇
/s/
----------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇
/s/
----------------------------------------
▇▇▇▇▇ ▇.▇. ▇▇▇▇▇▇▇
/s/
----------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇
[Signature Page to Release Agreement, cont.]
7